TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11932276
Drug: Flaxseed (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40 g daily for 3 months)
Study: 11932276
Drug: Wheat-based comparative
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat-based comparative control regimen (40 g daily for 3 months)
Study: 9795409
Drug: BMT (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT (bismuth subsalicylate 600 mg t. i. d. for 28 days, metronidazole 400 mg t. i. d. and tetracycline 500 mg q. i. d. for ten days)
Study: 9795409
Drug: OA (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA (omeprazole 40 mg o. d. and amoxicillin 750 mg q. i. d. for 14 days)
Study: 9795409
Drug: OC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC (omeprazole 40 mg o. d. and clarithromycin 500 mg b. i. d. for 14 days)
Study: 9795409
Drug: OT (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT (omeprazole 40 mg o. d. and tetracycline 500 mg q. i. d. for 14 days)
Study: 9795409
Drug: OMC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (omeprazole 40 mg o. d., metronidazole 400 mg t. i. d. and clarithromycin 250 mg b. i. d. for seven days)
Study: 8578768
Drug: DV‐7751a 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DV‐7751a 100 mg
Study: 8578768
Drug: DV‐7751a 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DV‐7751a 200 mg
Study: 8578768
Drug: DV‐7751a 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DV‐7751a 400 mg
Study: 8578768
Drug: DV‐7751a 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DV‐7751a 800 mg
Study: 421671
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg xipamide daily
Study: 421671
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg xipamide daily
Study: 30883864
Drug: LSD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (100 μg)
Study: 24079847
Drug: Preparation intervention
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation intervention involving practice and feedback with cross-examination questions
Study: 19781211
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (high dose)
Study: 19781211
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg (low dose)
Study: 11059437
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus bi‐weekly automated assessment and self‐care education calls with telephone follow‐up by a nurse educator
Study: 8358980
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of methotrexate (2.5mg oral daily doses, totaling 15 mg weekly)
Study: 8358980
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing of methotrexate (15 mg)
Study: 3526734
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 120 mg/day (6 X 20 mg)
Study: 29863691
Drug: Cellex (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellex (0.1 mg daily for 10 days)
Study: 27167103
Drug: ivabradine and
Normalized name: carvedilol and ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine and beta-blockers
Study: 27167103
Drug: beta-blockers alone
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blockers alone
Study: 25862567
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Study: 18037940
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT) and stem cell support
Study: 1723288
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (observation)
Study: 18037940
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with CHUT
Study: 12623421
Drug: Radiotherapy (involved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (involved field doses range from 40 to 48 Gy, median 44.5 Gy)
Study: 12623421
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (radiotherapy followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, by six cycles)
Study: 10390385
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals
Study: 30632847
Drug: Asparaginase treatment
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase treatment
Study: 27555294
Drug: Concomitant dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant dexamethasone therapy
Study: 22780999
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day ginseng
Study: 22780999
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day ginseng
Study: 22780999
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day ginseng
Study: 19534023
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg/d for 2 months
Study: 17024220
Drug: Postoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative steroid drops
Study: 17024220
Drug: Single sub‐tenon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sub‐tenon injection of triamcinolone
Study: 15042637
Drug: Caregiver skill‐building
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver skill‐building (CSB) treatment intervention
Study: 3414729
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg phenylpropanolamine
Study: 3414729
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg phenylpropanolamine plus 400 mg caffeine
Study: 3414729
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg phenylpropanolamine
Study: 31982647
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation intervention administered in a 16-week freshman orientation course
Study: 25514515
Drug: iTBS (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTBS (intermittent theta burst stimulation) applied daily over dPMCright during a four-day hand training program using mirror training (MT) for 20 minutes daily.
Study: 25514515
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation (control group CG) during the same four-day hand training program using mirror training (MT) for 20 minutes daily.
Study: 21564047
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Study: 21564047
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Study: 9810030
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata gum resin 300 mg thrice daily for 6 weeks
Study: 9810030
Drug: Lactose 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose 300 mg thrice daily for 6 weeks (Control)
Study: 2667311
Drug: urapidil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil (60 mg twice daily)
Study: 2667311
Drug: captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (25 mg twice daily)
Study: 31454356
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNSs) provided monthly during screenings.
Study: 15246460
Drug: 2-deoxyglucose (2-DG)
Normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxyglucose (2-DG) 40 mg/kg, i.v.
Study: 30482135
Drug: Warm fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm fluid bolus (500 mL of Ringer's acetate at 38°C)
Study: 30482135
Drug: Cold fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold fluid bolus (500 mL of Ringer's acetate at 22°C)
Study: 25166221
Drug: BF Spiromax
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF Spiromax 160+9 μg b.i.d.
Study: 25166221
Drug: Symbicort Turbohaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbohaler 200+12 μg b.i.d.
Study: 10916717
Drug: 3-day family
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day family medicine preceptorship
Study: 31412770
Drug: QLB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLB group (0.4 cc/kg of 0.3% ropivacaine)
Study: 31412770
Drug: C group
Normalized name: chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C group (0.4 cc/kg of 0.9% saline)
Study: 29943093
Drug: Levodopa/carbidopa (100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa (100/25 mg)
Study: 27765726
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (30 mg/250 ml) gastric infusion for 6 hours
Study: 27765726
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (30 mg) immediate-release tablets
Study: 27765726
Drug: Gastric infusion
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric infusion of trospium chloride
Study: 21987386
Drug: Upfront zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Upfront zoledronic acid (4 mg intravenously every 6 months for 5 years)
Study: 21987386
Drug: Delayed-start zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed-start zoledronic acid (4 mg intravenously every 6 months for 5 years)
Study: 15907848
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg/day) and Vitamin E (400 IU/day)
Study: 8320005
Drug: Soft laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft laser treatment (As-Ga and He-Ne)
Study: 3529799
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine (10 mg/day for 3 days)
Study: 3529799
Drug: Oral neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neostigmine (45 mg/day for 3 days)
Study: 3529799
Drug: Intravenous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physostigmine (1 mg)
Study: 3529799
Drug: Intravenous neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neostigmine (1.5 mg)
Study: 31265100
Drug: Tanezumab 2.5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5/5 mg
Study: 22566747
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (ExQW)
Study: 26214887
Drug: Gukang Capsules
Normalized name: Guang Guo Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gukang Capsules plus Calcium Carbonate Tablets
Study: 26214887
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium Carbonate Tablets
Study: 23953056
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg/d continuously
Study: 23953056
Drug: Lapatinib 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250 mg/d continuously plus capecitabine 2000 mg/m2 per day on days 1-14 of each 21-d cycle
Study: 21148503
Drug: Chloroquine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (50 mg/kg, 6 divided doses over 3 days)
Study: 18324564
Drug: Pharmacotherapy-aided quit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy-aided quit attempt
Study: 8922792
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg daily (with some patients receiving 800 mg for part of treatment)
Study: 8922792
Drug: Fluconazole 800
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 800 mg daily
Study: 28167470
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with Shexiang baoxin pills therapy
Study: 28167470
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy (Control)
Study: 26319228
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) infusion set (microneedle design B)
Study: 26319228
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) infusion set (Rapid-D)
Study: 26319228
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) infusion set
Study: 26319228
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) devices (MiniMed and Animas pumps)
Study: 26319228
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) and Subcutaneous (SC) infusion sets
Study: 19090877
Drug: Trandolapril/verapamil SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/verapamil SR (T/V) fixed-dose combination (FDC)
Study: 19090877
Drug: Benazepril/amlodipine (B/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril/amlodipine (B/A) fixed-dose combination (FDC)
Study: 16868321
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1 mL of 2% prilocaine using the peppering technique
Study: 16868321
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 2% prilocaine combined with 2 mL of autologous blood
Study: 16868321
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 2% prilocaine mixed with 40 mg of methylprednisolone acetate
Study: 12956200
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nail lacquer with oral antifungal agent
Study: 12956200
Drug: Other topical
Normalized name: Other topical products for joint and muscular pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other topical agents
Study: 6142748
Drug: Oral pirbuterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pirbuterol 15 mg
Study: 6142748
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (500 microgram and 5 mg)
Study: 28986072
Drug: Medication abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication abortion
Study: 25456022
Drug: Cumin powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumin powder (3 g/d with yogurt for 3 months)
Study: 14741074
Drug: Sympathyl (study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sympathyl (study drug)
Study: 27460262
Drug: Pectin-coated fortified
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin-coated fortified rice with 400 μg 13C5-PteGlu
Study: 27460262
Drug: Uncoated fortified
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated fortified rice with 400 μg 13C5-PteGlu
Study: 27460262
Drug: Aqueous 400
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous 400 μg 13C5-PteGlu
Study: 26047890
Drug: Esmirtazapine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine 1.5 mg
Study: 26047892
Drug: Esmirtazapine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine 4.5 mg
Study: 16317969
Drug: Custom trays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom trays with 10% carbamide peroxide gel worn overnight for 2 weeks
Study: 16317969
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide polyethylene strips worn for 30 minutes twice a day for 2 weeks
Study: 9596324
Drug: Atropine premedication
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine premedication (0.6 mg)
Study: 9596324
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (1 mL)
Study: 7674696
Drug: Current therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapies for acute ischemic syndromes
Study: 1982831
Drug: EPO subcutaneous
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO subcutaneous route (s.c) at doses of 20 u/kg daily
Study: 1982831
Drug: EPO subcutaneous
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO subcutaneous route (s.c) at doses of 2000 units twice a week
Study: 1982831
Drug: EPO intraperitoneal
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO intraperitoneal route (i.p) at doses of 4000 u/day, three days a week
Study: 1982831
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of EPO doses and outcomes between groups
Study: 369361
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg atropine sulfate
Study: 26111923
Drug: Tailored post-session
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored post-session D-cycloserine (DCS) administration
Study: 15230794
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg intramuscular)
Study: 15230794
Drug: Hyoscine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (20 mg intramuscular)
Study: 11878523
Drug: Epidural 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.2% bupivacaine 8 ml h(‐1) (bupi group)
Study: 11878523
Drug: Epidural 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.2% bupivacaine/morphine 50 microg at 4 ml h(‐1) (bupi/morph group)
Study: 8169617
Drug: Nimodipine administration
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine administration
Study: 31233255
Drug: Intrathecal ziconotide
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal ziconotide (average dose of 7.2µg per day)
Study: 27914822
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate 16 g/m2 intravenously 6 hours after each cisplatin dose
Study: 20032496
Drug: (SC)GOS/(LC)FOS/AOS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (SC)GOS/(LC)FOS/AOS (1.5 g . kg(‐1) . d(‐1))
Study: 15819987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IVC + and IVR < 1
Study: 11835452
Drug: Nabilone (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (synthetic cannabinoid receptor agonist)
Study: 2301717
Drug: Combined systemic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined systemic clindamycin and topical ampicillin
Study: 7470203
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of cholestyramine twice daily
Study: 7470203
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g of cholestyramine twice daily
Study: 7470203
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g of cholestyramine daily
Study: 7470203
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g of cholestyramine daily
Study: 28426903
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (Btx‐A) - 50 units in 2.5 ml sterile saline
Study: 28426903
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline (placebo) - 2.5 ml
Study: 25616206
Drug: Intravenous Mg
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Mg sulphate 40 mg kg(‐1) followed by an infusion of 10 mg kg(‐1) h(‐1)
Study: 23348071
Drug: First quartile
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First quartile of fruit intake (23 g/day)
Study: 17530683
Drug: Operant-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant-behavioral therapy (OBT)
Study: 16490090
Drug: Both propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both propofol formulations (LCT and MCT/LCT)
Study: 14658184
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding 48 to 72 hours after total laryngectomy
Study: 14658184
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding 10 to 12 days after total laryngectomy
Study: 6410450
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (up to 600 mg)
Study: 28850681
Drug: 8-mg dexamethasone
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg dexamethasone every 8 hours for up to 4 days after surgery
Study: 23871259
Drug: Oral pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pressure therapy (OPT)
Study: 16940094
Drug: Amoxicillin (AMX)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (AMX) 2 g